Overview

Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Tegaserod (HTF919) is an aminoguanidine indole compound and a member of a new class of subgroup-selective 5-hydroxytryptamine (5-HT) agonists. The aim of this study is to investigate the efficacy, safety and tolerability of tegaserod on bowel habits in patients with CC.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Tegaserod